

Glenmark Pharmaceuticals (Australia) Launches ATOVACUE (Atovaquone) Oral Liquid Suspension 750mg in 5mL

Expanding access to high-quality, affordable medicines in the Australian market

Sydney, February 18th, 2025: Glenmark Pharmaceuticals (Australia) Pty Ltd, a subsidiary of Glenmark Pharmaceuticals Ltd., a global, research led pharmaceutical company, announced the launch of ATOVACUE® (Atovaquone) Oral Liquid Suspension 750mg in 5mL, in the Australian market.

This launch marks a significant milestone as Glenmark enters the hospital generic prescription segment in Australia, reflecting the company's strategic commitment to broadening its presence in the region. With the introduction of ATOVACUE® (Atovaquone), Glenmark continues to enhance access to high-quality, affordable medicines, reinforcing our commitment to improving healthcare outcomes across the region.

ATOVACUE® is Glenmark's third product to be introduced in the Australian market. The company plans to introduce additional products over the next 12 months across key therapeutic areas including respiratory, dermatology, and oncology, positioning the company for continued expansion and long-term leadership in the Australian market.

Michael Moffitt, Country Manager, Australia & New Zealand, Glenmark Pharmaceuticals Ltd. said, "The launch of ATOVACUE® is an important milestone in our growth strategy. This launch aligns with our broader strategy to provide accessible, high-quality treatment options that address the evolving needs of patients. Over the coming year, we will continue to expand our portfolio across critical therapeutic areas, reinforcing our commitment to advancing patient care and strengthening Australia's healthcare ecosystem."

PBS Information: ATOVACUE® is listed on the PBS. Further information can be found here: <https://www.pbs.gov.au/medicine/item/8300W>

Healthcare professionals are requested to refer to the full Product Information before prescribing, available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2024-PI-01856-1&d=20250122172310101>

For Pharmacies and Hospitals:

The product can be ordered through all major wholesalers. Any inquiries related to ordering, please contact your Glenmark Business Advisor at 0412387087

---End---

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 Biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and Biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted more than 3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

Global Media Contact:

corpcomm@glenmarkpharma.com